Drug Name:
PRED MILD Rx
Generic Name and Formulations:
Prednisolone acetate 0.12%; oph. susp; contains benzalkonium chloride, sulfites.
Company:
Allergan
Therapeutic Use:
Indications for PRED MILD:
Ocular inflammation.
Adults and Children:
Instill 1–2 drops 2–4 times daily. During the initial 24–48hrs, the dosing frequency may be increased if needed.
Contraindications:
Fungal, mycobacterial, viral (except herpes zoster) or untreated bacterial infections.
Warnings/Precautions:
Corneal or scleral thinning. Glaucoma. Myopia. Diabetes. Asthma. Monitor for secondary infections and intraocular pressure in prolonged use. May mask or exacerbate infections. Avoid abrupt cessation. Re-evaluate if no improvement after 2 days. Pregnancy. Nursing mothers.
See Also:
Pharmacological Class:
Steroid.
Adverse Reactions:
Increased intraocular pressure, posterior subcapsular cataract formation, delayed wound healing, corneal perforations, optic nerve damage, defects in visual acuity and fields of vision, allergic reactions, dysgeusia, eye pain, foreign body sensation, headache, others.
How Supplied:
Mild—5mL, 10mL; Forte—5mL, 10mL, 15mL
Sign Up for Free e-newsletters
ONA Articles
- Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Adding Bevacizumab to First-line Chemotherapy Benefits Selects Cases of Ovarian Cancer
- Assessing Direct Costs of Treatment-Related Adverse Events in Advanced Melanoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Health Domains May Mediate Psychological Risk in Survivors of Childhood Leukemia
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |